Current status of cell-based therapies for COVID-19: evidence from mesenchymal stromal cells in sepsis and ARDS

Z Xu, Y Huang, J Zhou, X Deng, W He, X Liu… - Frontiers in …, 2021 - frontiersin.org
The severe respiratory consequences of the coronavirus disease 2019 (COVID-19)
pandemic have prompted the urgent need for novel therapies. Cell-based therapies …

Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential

E Gorman, J Millar, D McAuley… - Expert review of …, 2021 - Taylor & Francis
Introduction: Mesenchymal stromal (stem) cell (MSC) therapies are emerging as a promising
therapeutic intervention in patients with Acute Respiratory Distress Syndrome (ARDS) and …

[HTML][HTML] Mesenchymal stromal cells as potential immunomodulatory players in severe acute respiratory distress syndrome induced by SARS-CoV-2 infection

P Mallis, E Michalopoulos… - World Journal of Stem …, 2020 - ncbi.nlm.nih.gov
Severe acute respiratory syndrome coronavirus-2 and the related coronavirus disease-19
(COVID-19) is a worldwide emerging situation, which was initially reported in December …

Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential

M Khoury, PRM Rocco, DG Phinney, M Krampera… - Cytotherapy, 2020 - Elsevier
The serious consequences of the global coronavirus disease 2019 (COVID-19) pandemic
have prompted a rapid global response to develop effective therapies that can lessen …

Mesenchymal stromal cells in viral infections: implications for COVID-19

JLM Rocha, WCF de Oliveira, NC Noronha… - Stem cell reviews and …, 2021 - Springer
Mesenchymal stromal cells (MSCs) constitute a heterogeneous population of stromal cells
with immunomodulatory and regenerative properties that support their therapeutic use …

Mesenchymal stromal cells for sepsis and septic shock: lessons for treatment of COVID-19

C Laroye, S Gibot, C Huselstein… - Stem cells …, 2020 - academic.oup.com
Sepsis is defined as life-threatening organ dysfunction caused by a deregulated immune
host response to infection. The emergence of the severe acute respiratory syndrome …

Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome

W Qu, Z Wang, JM Hare, G Bu… - Stem Cells …, 2020 - academic.oup.com
Severe cases of COVID-19 infection, often leading to death, have been associated with
variants of acute respiratory distress syndrome (ARDS). Cell therapy with mesenchymal …

Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy

I Barros, A Silva, LP de Almeida, CO Miranda - Cytokine & Growth Factor …, 2021 - Elsevier
The devastating global impact of the Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) has prompted scientists to develop novel strategies to fight Coronavirus …

Mesenchymal stem/stromal cell therapy for COVID-19 pneumonia: potential mechanisms, current clinical evidence, and future perspectives

W Yao, L Shi, Y Zhang, H Dong, Y Zhang - Stem Cell Research & Therapy, 2022 - Springer
Abstract The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread into more than 200 countries …

Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome?

H Hamdan, SK Hashmi, H Lazarus, RP Gale, W Qu… - Blood Reviews, 2021 - Elsevier
Mesenchymal stromal cells (MSC) have immune regulatory and tissue regenerative
properties. MSCs are being studied as a therapy option for many inflammatory and immune …